TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Thursday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Stock Up 2.1 %

TherapeuticsMD stock opened at $1.92 on Thursday. The company has a 50 day moving average price of $2.23 and a 200-day moving average price of $2.31. TherapeuticsMD has a fifty-two week low of $1.86 and a fifty-two week high of $4.73.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC purchased a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.